Satsuma Pharmaceuticals, Inc.
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
September 10, 2019
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: | Mark Brunhofer, Senior Accounting Examiner |
Jim Rosenberg, Senior Assistant Chief Accountant
Irene Paik, Attorney Advisor
Joseph McCann, Staff Attorney
Re: | Satsuma Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333- 233347) |
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-233347) (the Registration Statement) of Satsuma Pharmaceuticals, Inc. (the Company). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 12, 2019, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Brian Cuneo at (650) 463-3014.
Thank you for your assistance in this matter.
Very truly yours, | ||
SATSUMA PHARMACEUTICALS, INC. | ||
By: |
/s/ John Kollins | |
John Kollins | ||
President and Chief Executive Officer |
CC: | Tom ONeil, Satsuma Pharmaceuticals, Inc. |
Alan Mendelson, Latham & Watkins LLP |
Brian Cuneo, Latham & Watkins LLP |
Miles Jennings, Latham & Watkins LLP |
Kenn Guernsey, Cooley LLP |
Sean Clayton, Cooley LLP |
September 10, 2019
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: | Mark Brunhofer |
Re: | Satsuma Pharmaceuticals, Inc. |
Registration Statement on Form S-1 (File No. 333-233347) |
Ladies and Gentlemen:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the Securities Act), we wish to advise that as of the time of this filing, the underwriters have not yet made any distribution of the Preliminary Prospectus of Satsuma Pharmaceuticals, Inc. (the Registrant) dated September 3, 2019. However, the underwriters are taking steps to see that all underwriters, brokers or dealers participating in the public offering of shares of the Registrants common stock pursuant to the above-captioned Registration Statement, as amended (the Registration Statement), are promptly furnished with sufficient copies of the preliminary and final prospectus to enable them to comply with the prospectus delivery requirements of Sections 5(b)(1) and (2) of the Securities Act.
We wish to advise you that the participating underwriters have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement be accelerated to 4:30 p.m. Eastern Time, on Thursday, September 12, 2019 or as soon thereafter as practicable.
[signature page follows]
Very truly yours, | ||
CREDIT SUISSE SECURITIES (USA) LLC SVB LEERINK LLC EVERCORE GROUP L.L.C. | ||
As representatives of the Underwriters | ||
CREDIT SUISSE SECURITIES (USA) LLC | ||
By: |
/s/ Joshua Pinto | |
Name: |
Joshua Pinto | |
Title: |
Director | |
SVB LEERINK LLC | ||
By: |
/s/ Murphy Gallagher | |
Name: |
Murphy Gallagher | |
Title: |
Managing Director | |
EVERCORE GROUP L.L.C. | ||
By: |
/s/ James T. Chandler | |
Name: |
James T. Chandler | |
Title: |
Senior Managing Director |
[Signature Page to Acceleration Request Letter]